[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypercalcemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypercalcemia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,62,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100384944","hypercalcemia-after-paraffin-oil-injection-100384944",false,"NCT04292288","Hypercalcemia After Paraffin Oil Injection","Hypercalcemia After Paraffin Oil Injection: Aetiology, Pathogenesis and Possible Treatment Options","Inclusion Criteria: - previous injection of paraffin oil into the body\n\n\\-\n\nExclusion Criteria: - inability to walk\n\n* inability to understand the consequences of inclusion\n* incurable cancer disease","MALE","18 Years","80 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","Today, there is an increased use of non-medical, invasive cosmetic treatments globally without sufficient awareness of possible health risks. A particular problem is young men injecting large amounts of paraffin oil into skeletal muscles especially on upper arms and chest to increase the visible size of the muscles. Several case reports have suggested that intramuscular injection of paraffin oil induces foreign body reaction and granuloma formation and subsequently hypercalcemia. Our hypothesis is that increased generation of activated vitamin D (1,25(OH)2D3) in the marcrophages may be responsible for the persistent hypercalcemia. Now trhe investigators want to include a large group of men who injected 100-10.000 ml paraffin oil to identify risk factors for developing hypercalcemia and try to understand the pathogenesis of the disease. Additionally, granuloma tissue from selected patients will be cultured ex vivo to investigate whether they produce 1,25(OH)2D3 or PTHrP and to test which drugs can most effectively be used to lower calcium levels in these men. Subsequently, we will try to stratify the men according to the severity of the changes in calcium homeostasis as we suggest that this stratification will be the basis for future intervention trials",[25,26],"Hypercalcemia","Granuloma","RECRUITING","2025-04-02",{"date":30,"type":31},"2025-04-06","ACTUAL",{"date":33,"type":31},"2019-04-01",{"date":35,"type":21},"2029-01-01",{"name":37,"class":38},"Martin Blomberg Jensen","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":39},"100382897","exploring-pathogenesis-and-treatment-of-hypercalcemia-caused-by-intramuscular-injection-of-paraffinoil-100382897","NCT04265599","Exploring Pathogenesis and Treatment of Hypercalcemia Caused by Intramuscular Injection of Paraffinoil","Hypercalcemia After Cosmetic Paraffin Oil Injections: Unravelling Etiology, Pathogenesis and Potential Treatments","Inclusion Criteria:\n\n* previous intramuscular injection of paraffin or other oil\n\nExclusion Criteria:\n\n* none","ALL",{"count":20,"type":21},"The aim of the study is to characterize paraffin oil induced granulomatous disease. We will investigate pathogenesis and natural history of paraffin disease. Subsequently, through further translational studies, we intend to identify novel treatments to be tested in future randomized clinical trials.",[25,51,52],"Renal Injury","Paraffinoma","2024-09-30",{"date":55,"type":31},"2024-10-01",{"date":57,"type":31},"2019-04-30",{"date":59,"type":21},"2027-01-31",{"name":61,"class":38},"Herlev Hospital",{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":39},"100357587","phase-4-calcitonin-pre-treatment-to-improve-spect-ct-sensitivity-100357587","NCT03935984","Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity","Improving the Sensitivity of Sestamibi SPECT-CT Parathyroid Scan with Calcitonin Pre-treatment for Primary Hyperparathyroidism","Inclusion Criteria:\n\n* Diagnosis of primary hyperparathyroidism\n* Non-localizing SPECT-CT performed within 365 days prior to consent to participate in study\n* Patient desires surgical intervention for treatment of PHPT\n* No contraindications to 99mTC-Sestamibi\n* No contraindications to treatment with calcitonin\n* Serum calcium level prior to non-localizing SPECT-CT is ≥10.5 mg\u002FdL\n* Patient consents to participate and undergo second SPECT-CT for purposes of research\n\nExclusion Criteria:\n\n* Previous surgery to the neck, including resection of parathyroid tissue, except where end organ damage is present and further surgical intervention is medically necessary\n* Contraindication to 99mTC-Sestamibi SPECT-CT as evidenced by allergic reaction or adverse event during index SPECT-CT\n* Allergy to calcitonin\n* Hypocalcemia (contraindication to calcitonin)\n* Vitamin D deficiency (contraindication to calcitonin)\n* Previous treatment with radioactive iodine\n* New prescription of thyroid medication (levothyroxine, armour thyroid tablets, etc. must be taken at time of index scan and research scan)\n* Lithium exposure within one year of SPECT-CT (index and research scans)\n* Secondary hyperparathyroidism\n* Benign familial hypocalciuric hypercalcemia\n* Known malignancy, particularly multiple endocrine neoplasia\n* New prescription of thiazide diuretic, (thiazide diuretic must have been taken at the time of index scan and second scan)\n* Currently taking calcium channel blockers\n* Pregnancy",{"count":70,"type":21},37,"INTERVENTIONAL",[73],"PHASE4","Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake\u002Fretention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.",[76,25],"Primary Hyperparathyroidism","2024-09-16",{"date":79,"type":31},"2024-09-19",{"date":81,"type":31},"2019-05-29",{"date":83,"type":21},"2026-12-31",{"name":85,"class":38},"Joseph Sferra",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":39},"100484250","registry-for-hypoparathyroidism-wuerzburg-100484250","NCT05585593","Registry for Hypoparathyroidism Wuerzburg","Registry and Biobank for Patients With Hypoparathyroidism Wuerzburg","Inclusion Criteria:\n\n* age of 18\n* chronic hypoparathyroidism (\\>12 months) under established therapy or chronic pseudohypoparathyroidism (\\>12 months) under established therapy\n* written informed consent\n\nExclusion Criteria:\n\n* age \\\u003C18 years\n* no detailed documentation of hypo- or pseudohypoparathyroidism",{"count":94,"type":21},300,"Long-term conventional treatment of chronic hypoparathyroidism does not fully restore calcium homeostasis leading to increased morbidity, emergency events and reduced subjective health status. To further investigate general morbidity, hypocalcemic events, subjective and daily life performance in patients with chronic hypoparathyroidism a standardized interview as well as blood sampling and examinations such as echocardiography and renal ultrasound are performed.",[97,98,99,25,100],"Comorbidities and Coexisting Conditions","Morality","Hypocalcemia","Quality of Life","2022-11-02",{"date":103,"type":31},"2022-11-08",{"date":105,"type":31},"2017-10-18",{"date":107,"type":21},"2032-01-01",{"name":109,"class":38},"University of Wuerzburg"]